阿替利珠单抗联合贝伐珠单抗在Child-Pugh A级和B级肝硬化肝细胞癌患者中的安全性与耐受性初步证据:一项真实世界研究
该真实世界研究回顾性纳入11个三级中心连续接受阿替利珠单抗联合贝伐珠单抗治疗的216例肝细胞癌患者,其中Child-Pugh A级154例(76%)、B级48例(24%)。中位随访9.0个月(95%CI 7.8-10.1),中位总生存期14.9个月(95%CI 13.6-16.3),中位无进展生存期6.8个月(95%CI 5.2-8.5),客观缓解率25%、疾病控制率73%。Child-Pugh B级与A级患者的治疗相关不良事件发生率相当,作者认为需在该治疗受限人群中开展前瞻性评估。
要点
- Child-Pugh B级与A级患者的治疗相关不良事件发生率相当。
- 中位总生存期14.9个月,中位无进展生存期6.8个月。
- 客观缓解率25%、疾病控制率73%,Child-Pugh分级间无差异。
核心结论
- 本研究证实阿替利珠单抗联合贝伐珠单抗在常规实践中的安全性和疗效具有可重复性。
- Child-Pugh B级患者报告了与Child-Pugh A级相似的可耐受性,作者认为需在该治疗受限人群中开展前瞻性评估。
研究设计与样本
- 回顾性研究,纳入11个三级中心连续接受阿替利珠单抗联合贝伐珠单抗治疗的216例肝细胞癌患者。
- 分析纳入按说明书治疗的全部患者(n=202,94%)。
- 按常见不良事件评价标准v5.0对治疗相关不良事件进行分级。
- 采用实体瘤疗效评价标准v1.1评估总生存期、无进展生存期、客观缓解率和疾病控制率。
主要发现
- 疾病主要继发于病毒性肝炎,丙型肝炎72例(36%)、乙型肝炎35例(17%)。
- 肝功能Child-Pugh A级154例(76%)、B级48例(24%)。
- 143例(71%)报告任何级别治疗相关不良事件,其中53例(26%)为G3、3例(2%)为G4。
- 与Child-Pugh A级相比,Child-Pugh B级患者的治疗相关不良事件发生率相当。
- 治疗前食管胃十二指肠镜检查所见静脉曲张的存在及分级与出血事件不相关。
关键数值与推荐
- 治疗相关不良事件按常见不良事件评价标准v5.0分级。
- 疗效按实体瘤疗效评价标准v1.1定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function. APPROACH AND RESULTS: In 216 patients with HCC who were consecutively treated with AtezoBev across 11 tertiary centers, we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to Common Terminology Criteria for Adverse Events v5.0, including in the analysis all patients treated according to label (n = 202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR), and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors v1.1. Disease was mostly secondary to viral hepatitis, namely hepatitis C (n = 72; 36%) and hepatitis B infection (n = 35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared with CP-A, patients with CP-B showed comparable rates of trAEs. Presence and grade of varices at pretreatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95% CI, 7.8-10.1), median OS was 14.9 months (95% CI, 13.6-16.3), whereas median PFS was 6.8 months (95% CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. CONCLUSIONS: This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP-B reported similar tolerability compared with CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.
引用
- D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022. PMID: 35313048. doi:10.1002/hep.32468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。